Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GT 10

X
Drug Profile

GT 10

Alternative Names: DNA encoded personalised vaccine - Geneos Therapeutics; GEN-PV-001

Latest Information Update: 04 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Geneos Therapeutics
  • Developer Geneos Therapeutics; Washington University School of Medicine
  • Class Antigens; Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Anaplastic astrocytoma

Most Recent Events

  • 21 Jul 2021 The US FDA accepts a compassionate use single patient Investigational New Drug application for a clinical trial in anaplastic astrocytoma
  • 04 Jun 2021 Preclinical trials in Anaplastic astrocytoma in USA (unspecified route), prior to June 2021
  • 04 Jun 2021 Adverse events and efficacy data from a clinial trial in Anaplastic astrocytoma presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top